A new genetic variant involved in genetic susceptibility to alcoholic liver cirrhosis: -330T>G polymorphism of the interleukin-2 gene

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 9, 2008, Pages 855-859

  Marcos, Miguel ^a   Pastor, Isabel ^a,b   González Sarmiento, Rogelio ^b   Laso, Francisco Javier ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Alcoholic liver disease; Alcoholism; Cytokines; Interleukin 2 genetics; Polymorphism

Indexed keywords

INTERLEUKIN 2; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INHERITANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-2; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 56749098621     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282fd0db1     Document Type: Article

References (42)

1. Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res 1981; 5:207-215.
2. Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20:1528-1533.
3. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, et al. Cytokines and alcohol. qAlcohol Clin Exp Res 2006; 30:720-730.
4. Hines IN, Wheeler MD. Recent advances in alcoholic liver disease III. Role of the innate immune response in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2004; 287:G310-G314.
5. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497-G502.
6. Pastor IJ, Laso FJ, Romero A, Gonzalez-Sarmiento R. -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 2005; 29:1928-1931.
7. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26:143-146.
8. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46:540-545.
9. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
10. Santos-Perez JL, Diez-Ruiz A, Luna-Casado L, Soto-Mas JA, Wachter H, Fuchs D, Gutierrez-Gea F. T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. Immunol Lett 1996; 50:179-183.
11. Bird GL, Aria KN, Daniels H, Alexander GJ, Williams R. Contrasts in interleukin-1 and interleukin-2 activity in alcoholic hepatitis and cirrhosis. Alcohol Alcohol 1989; 24:541-546.
12. Vicente-Gutierrez MM, Diez Ruiz A, Gil Extremera B, Bermudez Garcia JM, Gutierrez Gea F. Low serum levels of alpha-interferon, gamma-interferon, and interleukin-2 in alcoholic cirrhosis. Dig Dis Sci 1991; 36:1209-1212.
13. Deviere J, Denys C, Schandene L, Romasco F, Adler M, Wybran J, Dupont E. Decreased proliferative activity associated with activation markers in patients with alcoholic liver cirrhosis. Clin Exp Immunol 1988; 72:377-382.
14. Laso FJ, Iglesias-Osma C, Ciudad J, Lopez A, Pastor I, Orfao A. Chronic alcoholism is associated with an imbalanced production of Th-1/Th-2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res 1999; 23: 1306-1311.
15. Latvala J, Hietala J, Koivisto H, Jarvi K, Anttila P, Niemela O. Immune Responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am J Gastroenterol 2005; 100:1303-1310.
16. Bozkaya H, Bozdayi M, Turkyilmaz R, Sarioglu M, Cetinkaya H, Cinar K, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology 2000; 47:1675-1679.
17. Sundstrom S, Ota S, Dimberg LY, Masucci MG, Bergqvist A. Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J Virol 2005; 79:2230-2239.
18. Chichester JA, Feitelson MA, Calkins CE. Transient inhibition of Th1-type cytokine production by CD4T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells. Immunology 2006; 118:438-448.
19. Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH, et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006; 44:1240-1249.
20. Degrave W, Tavernier J, Duerinck F, Plaetinck G, Devos R, Fiers W. Cloning and structure of the human interleukin 2 chromosomal gene. Embo J 1983; 2:2349-2353.
21. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE, et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet 1998; 25:419-420.
22. Togawa S, Joh T, Itoh M, Katsuda N, Ito H, Matsuo K, et al. Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter 2005; 10:172-178.
23. Matesanz F, Fedetz M, Collado-Romero M, Fernandez O, Guerrero M, Delgado C, Alcina A. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001; 119:101-105.
24. Erlinger JE, Benhamou JP. Cirrhosis: clinical aspects. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, editors. Textbook of clinical hepatology. Vol. 1. 2nd ed. Oxford: Oxford University Press; 1999. pp. 629-641.
25. Wu A, Slavin G, Levi AJ. Elevated serum gamma-glutamyl-transferase (transpeptidase) and histological liver damage in alcoholism. Am J Gastroenterol 1976; 65:318-323.
26. Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst Biol 2004; 53:793-808.
27. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72:1444-1450.
28. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. Association of cytokine gene polymorphisms and the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Int Immunopharmacol 2006; 6:351-357.
29. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4:583-594.
30. Hesse M, Cheever AW, Jankovic D, Wynn TA. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 2000; 157:945-955.
31. Reiman RM, Thompson RW, Feng CG, Hari D, Knight R, Cheever AW, et al. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun 2006; 74:1471-1479.
32. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 268:1472-1476.
33. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4 + T cells. Eur J Immunol 1995; 25:3053-3059.
34. Horak I, Lohler J, Ma A, Smith KA. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148:35-44.
35. Jerrells TR. Role of activated CD8 + T cells in the initiation and continuation of hepatic damage. Alcohol 2002; 27:47-52.
36. Duryee MJ, Willis MS, Freeman TL, Kuszynski CA, Tuma DJ, Klassen LW, Thiele GM. Mechanisms of alcohol liver damage: aldehydes, scavenger receptors, and autoimmunity. Front Biosci 2004; 9:3145-3155.
37. Bruguera M, Bordas JM, Rodes J. Asymptomatic liver disease in alcoholics. Arch Pathol Lab Med 1977; 101:644-647.
38. Martins A, Cortez-Pinto H, Machado M, Goncalves MS, Soren S, Marques-Vidal P, et al. Are genetic polymorphisms of tumour necrosis factor alpha, interleukin-10, CD14 endotoxin receptor or manganese superoxide dismutase associated with alcoholic liver disease? Eur J Gastroenterol Hepatol 2005; 17:1099-1104.
39. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-499.
40. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2:91-99.
41. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006; 41:209-224.
42. Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez O, Alcina A. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol 2004; 148:212-217.